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Abstract
Summary The effect of dopaminergic medication on the
risk of hip/femur fractures is not clear. Our results showed a
nearly twofold increased risk of hip/femur fractures in
current dopaminergic drug users. Concomitant use of
antidepressants further increased this risk. Fracture risk
assessment may be warranted in elderly users of dopami-
nergic drugs.
Introduction Dopaminergic drugs, often used in the treat-
ment of Parkinson’s disease, have several pharmacological
effects that may increase or decrease the risk of falling and
fractures. Thus, the effect of dopaminergic medication on
the risk of hip/femur fractures is not clear. The objective of
the study was to examine the effect of dopaminergic
medication and concomitant use of psychotropics on the
risk of hip/femur fractures taking into account the timing of
dopaminergic drug use.
Methods A population-based case–control study in the
PHARMO database was conducted for the period 1991 to
2002. Cases were patients aged 18 years and older with a
first hip or femur fracture and matched to four control
patients by year of birth, sex and geographical region.
Results The study population included 6,763 cases and
26,341 controls. Current use of dopaminergic drugs (1–
30 days before the index date) was associated with an
increased risk of hip/femur fractures compared to never use
(ORadj 1.76, 95% CI=1.39–2.22), but this excess risk
rapidly dropped to baseline levels when treatment had been
discontinued >1 year ago. Concomitant use of antidepres-
sants among current dopaminergic drug users further
increased the risk of hip/femur fractures (ORadj 3.51, 95%
CI=2.10–5.87) while there was no additional risk with
concomitant use of other psychotropics.
Conclusions Although the observed association between
dopaminergic drugs and fracture risk may not be entirely
causal, due to absence of information on the (severity of
the) underlying disease, fracture risk assessment may be
warranted in elderly users of dopaminergic drugs.
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Introduction
Dopaminergic drugs are commonly used in the treatment of
Parkinson’s disease (PD), a neurodegenerative movement
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DOI 10.1007/s00198-010-1455-3disorder characterised by tremor, rigidity, akinesia and
postural instability [1]. PD has a prevalence of approximate-
ly 0.5% to 1% among persons 65 to 69 years of age, rising
to 1–3% among persons 80 years of age and older [2].
Several studies have shown increased non-spine fracture
incidence rates in PD [3–6]. The main risk factors are falls
[7], due to the underlying balance disorder, and lower bone
mineral density (BMD) [5, 6], which may be caused by
immobilisation [8], inadequate vitamin D intake [9],
insufficient sun exposure [10] and a lower body mass
index (BMI) [11]. Falls are the most common primary
reason for emergency hospital admission in patients with
PD [12].
The effect of dopaminergic drugs on fracture risk is
relatively unexplored. Dopaminergic drugs can be divided
into the dopamine precursor, levodopa, and the direct-
acting dopamine agonists. Side effects associated with
dopaminergic drug use include orthostatic hypotension
[13], sudden onset of sleep [14], daytime sleepiness [15]
and dizziness, all of which may increase the risk of falls and
subsequent fractures. In addition, levodopa use can induce
hyperhomocysteinemia, which has been suggested as a
mechanistic risk factor for fractures [16]. In contrast,
several factors related to dopaminergic drug use may
reduce fracture risk. Treatment of PD with dopaminergic
drugs may improve the locomotor function and thus
prevent falls. Furthermore, although speculative, dopami-
nergic drugs may decrease fracture risk by suppressing
prolactin levels, thereby improving secretion of gonadal
steroids and thus increasing BMD [17, 18].
In a Danish epidemiological study, higher doses of
levodopa have been associated with an increased risk of hip
fractures [17]. This finding was explained by better
mobilisation of patients in the absence of completely
normalised movement patterns, leading to an increased risk
of falls and fractures. It remains unclear what the influence
is of continuous duration of use or discontinuation of
dopaminergic drugs on the risk of hip fractures.
A substantial number of patients with PD suffer from
depression (20–40%) [19] and concomitantly use antide-
pressants (23%) [20]. Both have been previously identified
as independent risk factors for hip fractures [21–23]. The
effect of concomitant use of dopaminergic drugs and
antidepressants on the risk of hip fractures is unclear. Also,
antipsychotics are used frequently in patients with PD (7-
year probability of use 35%) [24]. Its use has been
associated with a higher risk of hip/femur fractures [25,
26], but the effect of concomitant use of dopaminergic
drugs and antipsychotics has not been studied.
The aim of this study was to examine the association
between use of dopaminergic drugs and the risk of hip/
femur fractures and particularly the timing of dopaminergic
drug use and excess fracture risk. Furthermore, the effect of
concomitant use of psychotropic and dopaminergic drugs
on the risk of hip/femur fractures was evaluated.
Methods
Study design
We conducted a case–control study within the Dutch
PHARMO Record Linkage System (RLS) [Institute for
Drug Outcome Research, www.pharmo.nl]. The database
includes the demographic details and complete medication
histories for about one million community-dwelling resi-
dents in the Netherlands representing some 7% of the
general population. Almost every individual in the Nether-
lands is registered with a single community pharmacy,
independent of prescriber and irrespective of their health
insurance or socioeconomic status.
In the organisation of pharmaceutical care, Dutch
community pharmacies play a central role. These pharma-
cies are typically 3–4 times larger than their counterparts in
other Western European countries or North America,
having 8,000–14,000 patients per pharmacy. Pharmacy
networks in PHARMO typically comprise a sample of
pharmacies in different geographic regions, with careful
geographical selection of urban and rural community
pharmacies. The provision of pharmaceutical services from
Dutch pharmacies is population-based. Specific populations
(e.g. the very poor, the unemployed) are therefore not
excluded from pharmaceutical services. This is an impor-
tant issue with respect to external validity to populations
outside the PHARMO database. Validation studies on
PHARMO RLS have confirmed a high level of data
completeness and validity with regards to fractures [27, 28].
Study population
Data were collected for the period 1 January 1991 to 31
December 2002. Cases were patients aged 18 years and
older with a record for a first fracture of the hip or femur
during the study period. The index date was the date of
hospital admission. Each case was matched to up to four
control patients by year of birth, sex and geographical
region. Each control was assigned the same index date as
the corresponding case.
Exposure assessment
Exposure to dopaminergic drugs was determined by
reviewing dispensing information prior to the index date:
(a) dopamine agonists: bromocriptine, lisuride, pergolide,
ropinirole, pramipexole, cabergoline and apomorphine
(excluding the sublingual administration form) and (b)
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were prescribed for were not recorded in the PHARMO
database.
For each dispensing of a dopaminergic drug, the written
dosage instruction was used to estimate its exposure
episode. If a written dosage instruction was missing, the
median value of all dispensings was used. ‘Current’ users
were patients who were exposed to dopaminergic drugs
within the 30-day period before the index date. ‘Recent’
users had discontinued dopaminergic drugs between 31 and
182 days before the index date. ‘Past’ users had stopped
taking dopaminergic drugs >182 days before the index date.
Concomitant exposure to psychotropics [anticholinergics
(biperiden, dexetimide, orphenadrine, procyclidine, trihex-
yphenidyl), antidepressants, antipsychotics and benzodia-
zepines] was measured within the current dopaminergic
drug users. For each current dopaminergic drug user, the
continuous duration of use was determined by adding up all
dopaminergic exposure episodes before the index date. If
the period between two exposure episodes exceeded
3 months, this was considered a treatment gap. Exposure
episodes before a treatment gap were not added to the total
period of continuous duration of use.
Potential confounders
The records of cases and controls were reviewed for
evidence of potential confounders that have previously
been associated with fracture risk [29, 30]. These include
the following 30 variables: a recent history of hospital-
isation (in the previous year) for: mental disorders, and
skin/subcutaneous diseases; a history of hospitalisation at
any time for: impaired renal function, malignant neoplasm,
endocrine disorder, cardiovascular disease, cerebrovascular
disease, obstructive airway disease, inflammatory bowel
disease, musculoskeletal or connective tissue disease,
rheumatoid arthritis and PD; dispensing of a benzodiaze-
pine within 3 months before the index date; dispensing
within the previous 6 months of any of the following:
antipsychotics, bronchodilators, inhaled or oral cortico-
steroids, hormone replacement therapy, antidepressants,
antiarrhythmics, antiepileptics, thiazide diuretics, thyroid
hormones, antithyroid hormones, drugs for treatment of
diabetes, disease-modifying anti-rheumatic drugs, two or
more dispensings of a non-steroidal anti-inflammatory
drug; and current use of the following antiparkinsonian
drugs: amantadine, selegeline, tolcapone and entacapone.
Data analysis
Conditional logistic regression analysis was used to
estimate the risk of hip/femur fracture associated with the
use of dopaminergic drugs and were expressed as odds
ratios (OR) with corresponding 95% confidence intervals
(CI). Adjusted odds ratios (ORadj) for hip/femur fracture
were estimated after adjustment for the various confound-
ing variables. Final regression models included all potential
confounding factors that changed the natural logarithm of
the risk estimate with more than 5%.
Stratified analyses within current dopaminergic drug
users were performed regarding gender, age category, type
of current dopaminergic drug (dopamine agonist,
levodopa-containing drug, or combined use) and concom-
itant use of anticholinergics, antidepressants, antipsy-
chotics or benzodiazepines.
In order to differentiate between onset and offset of the
effect of dopaminergic drugs on hip/femur fractures, two
separate analyses were performed: (1) the onset was
investigated by calculating the risk of hip/femur fractures
in relation to continuous duration of dopaminergic drug use
within current users; (2) the offset was investigated by
calculating the risk of hip/femur fractures in relation to the
recency of use of dopaminergic drug treatment within ever
users. In both analyses, the dopaminergic drug users were
subdivided into 10 subgroups based on deciles of the
continuous duration of use (or recency of use). An OR was
calculated for each of the subgroups. Spline regression was
then used to smooth these estimates and to visualise any
trends. This method has been advocated as an alternative to
categorical analysis [31]. Analyses were performed with
SPSS 16.0. Spline regression was performed with SAS
9.1.3.
Results
We identified 6,763 cases with a fracture of the hip or
femur and 26,341 matched controls (Table 1). Almost
three-quarters (73%) of the study population was female.
The mean duration of follow-up before the index date was
5.8 years for cases and 5.7 years for controls. The median
age was 79 years for cases and controls. More details on
this particular dataset have been described elsewhere [26,
32, 33].
As shown in Table 2, the risk of hip/femur fractures was
nearly doubled among current users of dopaminergic drugs
compared to no use (ORadj=1.76, 95% CI=1.39–2.22). The
risk associated with current use of dopaminergic drugs was
significantly greater compared with past use (p=0.019).
Further stratified analyses suggested that the risk of hip/
femur fracture for current users of dopaminergic drugs were
not different for men and women. There were no risk
differences for individuals aged ≥70 years compared with
those younger than 70 years.
Table 3 shows that the risk of hip/femur fractures was
comparable among current users of dopamine agonists only,
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shows that concomitant use of antidepressants and dopa-
minergic drugs further increased the risk of hip/femur
fractures (ORadj=3.51, 95% CI=2.10–5.87). Concomitant
current use of dopaminergic drugs and anticholinergics or
antipsychotics or benzodiazepines did not significantly alter
the overall risk of hip/femur fractures.
Figure 1 shows that hip/femur fracture risk was
increased immediately after initiation of dopaminergic drug
therapy and that it remained more than twofold increased
Table 1 Characteristics of cases and controls
Cases (n=6,763), % Controls (n=26,341), % Crude OR [95% CI]
Gender
Male 1,834 (27.1) 7,203 (27.3)
Female 4,929 (72.9) 19,138 (72.7)
Age (years)
18–49 452 (6.7) 1,808 (6.9)
50–69 1,061 (15.7) 4,239 (16.1)
≥70 5,250 (77.6) 20,294 (77.0)
Hospitalisation before the index date
Cardiovascular disease 359 (5.3) 1,289 (4.9) 1.10 [0.98–1.25]
Cerebrovascular disease 296 (4.4) 565 (2.1) 2.12 [1.84–2.45]
Parkinson’s disease 23 (0.3) 41 (0.2) 2.24 [1.34–3.75]
Mental disorders 24 (0.4) 36 (0.1) 2.54 [1.51–4.27]
Drug use 6 months before the index date
Benzodiazepines
a 967 (14.3) 2,751 (10.4) 1.44 [1.33–1.56]
Antidepressants 643 (9.5) 1,343 (5.1) 2.00 [1.81–2.21]
Antipsychotics 412 (6.2) 921 (3.5) 1.79 [1.58–2.02]
Current drug use at index date
Amantadine 30 (0.4) 42 (0.2) 2.78 [1.74–4.44]
Selegeline 56 (0.8) 51 (0.2) 4.37 [2.98–6.41]
Anticholinergics 43 (0.6) 67 (0.3) 2.52 [1.72–3.70]
Cathechol-O-methyltransferase inhibitors 1 (0.0) 5 (0.0) 0.80 [0.09–6.85]
a3 months before the index date
Table 2 Use of dopaminergic drugs and risk of hip/femur fracture
Cases (n=6,763), % Controls (n=26,341), % Crude OR [95% CI] ORadj
a [95% CI]
Never use 6,578 (97.3) 25,996 (98.7) Reference Reference
Ever use 185 (2.7) 345 (1.3) 2.13 [1.77−2.56] 1.50 [1.22−1.84]
Among ever users of a dopaminergic drug
Past use (>182 days before the index date) 20 (0.3) 81 (0.3) 0.98 [0.59−1.60] 0.91 [0.55−1.51]
Recent use (31−182 days before the index date) 9 (0.1) 27 (0.1) 1.28 [0.60−2.73] 1.01 [0.47−2.20]
Current use (1−30 days before the index date) 156 (2.3) 237 (0.9) 2.62 [2.13−3.22] 1.76[1.39−2.22]
b
By gender
Male 45 (0.7) 64 (0.2) 2.83 [1.92−4.17] 1.84 [1.21−2.81]
Female 111 (1.6) 173 (0.7) 2.54 [1.99−3.24] 1.73 [1.32−2.26]
By age category (years)
18−69 13 (0.2) 20 (0.1) 2.60 [1.29−5.23] 1.54 [0.73−3.24]
≥70 143 (2.1) 217 (0.8) 2.62 [2.11−3.25] 1.78 [1.39−2.27]
aAdjusted for: (a) a history in the past year of hospitalisation for Parkinson’s disease; (b) use in the past 6 months of antidepressants; and (c) current use of
amantadine, selegeline and anticholinergics
bp=0.019 for current dopaminergic drug use versus past use
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significant differences between current users of a dopami-
nergic drug with a duration ≤1 year (ORadj=1.87, 95% CI=
1.29–2.73) and current users who had been taking the
dopaminergic drug >1 year (ORadj=1.69, 95% CI=1.28–
2.25). Figure 2 shows that after discontinuation of
dopaminergic treatment, the increased risk of hip/femur
fractures rapidly decreased and that it was no longer
increased after 1 year of discontinuation.
Discussion
Our results showed a nearly twofold increased risk of hip/
femur fractures in current dopaminergic drug users. Pro-
longed use did not substantially change this risk. After
discontinuation of dopaminergic treatment, the increased
risk of hip/femur fractures rapidly decreased and it was no
longer increased after 1year of discontinuation. Patients who
used dopaminergic drugs and antidepressants at the same
time had a 3.5-fold increased risk of hip/femur fracture.
The findings of this study are to some extent in line with
the findings of Vestergaard and coworkers [17]. They
reported an association between levodopa use and an
increased overall fracture risk and an increased hip fracture
risk with high doses of levodopa. In addition, they found an
association between dopamine agonists in median dose and
an increased hip fracture risk.
In our study, the duration of use in current dopaminergic
drug users did not substantially change the risk of hip/
femur fractures. We did notice an increase of the risk
estimate directly after initiation of the dopaminergic drug,
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Fig. 1 The risk of hip/femur fracture with continuous duration of
dopaminergic drug use among current users. Datapoints and spline
regression line represent adjusted OR (adjusted for the same
confounders as under Table 2)
Table 3 Current use of dopaminergic drugs and risk of hip/femur fracture by substance and concomitant use of anticholinergics, antidepressants,
antipsychotics or benzodiazepines
Cases (n=6,763) Controls (n=26,341) Crude OR [95% CI] ORadj
a [95% CI]
Among current users of a dopaminergic drug
By substance
Dopamine agonist alone 5 (0.1) 7 (0.0) 2.86 [0.91−9.00] 1.86 [0.56−6.19]
Levodopa alone 117 (1.7) 188 (0.7) 2.46 [1.95−3.11] 1.71 [1.32−2.21]
Combination of dopamine agonist and levodopa 34 (0.5) 42 (0.2) 3.28 [2.09−5.16] 1.98 [1.20−3.26]
By concomitant use
b
Anticholinergics
c
Yes 16 (0.2) 28 (0.1) 2.27 [1.23−4.20] 1.59 [0.83−3.05] (a)
No 140 (2.1) 209 (0.8) 2.67 [2.14−3.32] 1.89 [1.49−2.41] (a)
Antidepressants
Yes 31 (0.5) 30 (0.1) 4.16 [2.52−6.88] 3.51 [2.10−5.87]
d (b)
No 125 (1.8) 207 (0.8) 2.40 [1.91−3.00] 1.70 [1.31−2.20] (b)
Antipsychotics
Yes 17 (0.3) 29 (0.1) 2.29 [1.25−4.20] 1.43 [0.74−2.77]
No 139 (2.1) 208 (0.8) 2.67 [2.14−3.32] 1.80 [1.40−2.30]
Benzodiazepines
Yes 23 (0.3) 32 (0.1) 2.88 [1.68−4.92] 1.87 [1.07−3.28]
No 133 (2.0) 205 (0.8) 2.58 [2.06−3.22] 1.74 [1.35−2.24]
aAdjusted for the same confounders as under Table 2 ((a) except for anticholinergics, (b) except for antidepressants)
bConcomitant current use (1−30 days before the index date)
cAnticholinergics include biperiden, dexetimide, orphenadrine, procyclidine and trihexyphenidyl
dp=0.011 for concomitant versus no concomitant use of antidepressants
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fracture risk and not changes in BMD. This may be
explained by the fact that dopaminergic drugs could cause
postural hypotension, sudden onset of sleep, daytime
sleepiness and dizziness, which may lead to an increased
risk of falling [34]. One may expect that postural
hypotension occurs almost directly after initiation of
dopaminergic drug treatment.
The timing of use was found to be important: only
current use was associated with a nearly twofold increased
risk hip/femur fractures, and the increased risk of hip/femur
fractures rapidly decreased after discontinuation. This
corroborates the hypothesis that the increased risk is caused
by an increased risk of falling rather than an effect on
BMD. Unfortunately, we could not formally test this
hypothesis due the absence of data on both falls and
BMD in our data source.
As a result of potential improvement of BMD due to
suppression of prolactin, we hypothesised that dopaminer-
gic drugs could decrease the risk of hip/femur fractures [17,
18]. Even if dopaminergics have a benefit on BMD, it was
not sufficient to reduce fracture risk or to balance the
increase in fracture risk assumed to be a consequence of an
increased falls risk during the first 6–12 months of use. In
contrast, it was suggested that levodopa-induced hyper-
homocysteinemia could increase the risk of fracture through
a direct effect on the bone collagen cross-links [16].
However, in our study, the risk estimate for levodopa users
was not different from that of dopamine agonist users
alone, or the users of the combination of dopamine agonists
and levodopa. Thus, our data do not support this hypoth-
esis. A remark should be made that the group of users of
monotherapy dopamine agonists was relatively small.
A substantial number of patients with PD suffer from
depression and use antidepressants. Both have been
previously identified as independent risk factors for hip
fractures [21, 22]. Indeed, patients who used dopaminergic
drugs and antidepressants at the same time had the highest
risk of hip/femur fracture (ORadj=3.51, 95% CI=2.10–
5.87). There are several explanations for this finding.
Firstly, the increased risk of fractures may be simply related
to a further increased risk of falls [35]. Secondly, it has
been suggested that inhibition of the serotonin transporter
system by antidepressants have a detrimental effect on bone
microarchitecture, leading to a decreased bone strength and
a higher probability that a fall will result in a fracture [23].
Furthermore, depression itself has been associated with
fractures [22]. Treatment with other psychotropic drugs,
such as benzodiazepines, anticholinergics and antipsy-
chotics, is associated with an increased risk of hip/femur
fractures, probably caused by an increased risk of falls [25,
26, 36] and, for antipsychotics, caused by a decreased bone
mineralisation leading to weaker bones [37]. However, the
risk of hip/femur fracture was not further increased with
concomitant use of dopaminergic drugs and these psycho-
tropic drugs.
It is unclear whether the increased risk of hip/femur
fractures in users of dopaminergic drugs is related to the
pharmacological properties, the underlying disease or the
severity of the underlying disease. Van de Vijver et al. have
found that the use of antiparkinsonian drugs has a high
positive predictive value for PD in a population aged
55 years and older, especially when levodopa is used [38].
Although we do not have such information for other age
categories, we assume that dopaminergic drugs within our
cases and controls were mainly used to treat PD, a
progressive disease in which postural instability is one of
the main symptoms. Several studies have shown increased
non-spine fracture incidence rates in PD [3–6]. Parkinso-
nian patients have been associated with a higher risk of falls
[7] and with lower BMD [5, 6, 39]. A limitation is that we
had no data on the severity of the underlying disease.
However, we did correct for hospitalisation for PD in the
adjusted analysis although an inpatient hospitalisation for
PD may be a less sensitive measure of PD severity. One
may wonder which type of patients discontinued dopami-
nergic medication because these drugs are the only option
for the treatment of motor symptoms in PD. The patients
that discontinued dopaminergic drugs more than 1 year ago
did not differ from the current users with respect to age.
However, we cannot rule out that some discontinuators had
a diagnosis different from PD, such as restless legs
syndrome, and hence, a lower risk of falls and/or fractures.
Further limitations include absence of potentially confound-
ing data on body mass index, smoking status and exercise.
Low BMI, low exercise status and smoking are risk factors
for fractures [40, 41]. Low BMI and low exercise status
also are associated with PD [8, 11]. By not correcting for
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Fig. 2 The risk of hip/femur fracture and time since last dispensing
for a dopaminergic drug. Datapoints and spline regression line
represent adjusted OR (adjusted for the same confounders as under
Table 2)
2202 Osteoporos Int (2011) 22:2197–2204these potential confounders, we may have overestimated
the risk estimate. Smoking is suggested as a protective
factor for PD [42]. By not correcting for smoking status, we
may have underestimated the risk estimate. The strengths of
this study include the following: our population had a
substantial sample size and we had routinely collected
longitudinal data on drug exposure and hospitalisations.
Patients were included irrespective of socioeconomic status:
the study was population-based and provided real life data
on intake of dopaminergic drugs.
In conclusion, current dopaminergic drug use was
associated with a nearly twofold increased risk of hip/
femur fractures. Concomitant use of antidepressants, which
is common among patients with PD, further increased the
risk of hip/femur fractures. Although the observed associ-
ation between dopaminergic drugs and fracture risk may
not be entirely causal, fracture risk assessment may be
warranted in elderly users of dopaminergic drugs.
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